CORRECTION article

Front. Oncol., 13 December 2022

Sec. Molecular and Cellular Oncology

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1106553

Corrigendum: Heparin binding epidermal growth factor–like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma

  • 1. International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

  • 2. Oncology Center, Bai Chay Hospital, Quang Ninh, Ha Long, Vietnam

  • 3. Department of Thoracic and Neurological Surgery, Bai Chay Hospital, Quang Ninh, Ha Long, Vietnam

  • 4. Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

  • 5. Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

  • 6. TMU Research Center for Thoracic Medicine, Taipei Medical University, Taipei, Taiwan

  • 7. Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

  • 8. Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

In the published article, there was an error in affiliation 1. Instead of “IInternational Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan”, it should be “International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan”.

In the published article, there was an error in the Ethics statement. The IRB number was incorrectly displayed as “IRB no. N20210313”. The correct IRB number is “IRB no. N202103013”. The correct Ethics statement appears below.

Statements

Ethics statement

The study protocol was approved by the Joint Institutional Review Board of Taipei Medical University (IRB no. N202103013). The patients/participants provided their written informed consent to participate in this study.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

heparin-binding EGF-like growth factor (HBEGF), bioinformatics, biomarker, immune infiltration, macrophage chemotaxis, non-small cell lung cancer

Citation

Van Hiep N, Sun W-L, Feng P-H, Lin C-W, Chen K-Y, Luo C-S, Dung LN, Van Quyet H, Wu S-M and Lee K-Y (2022) Corrigendum: Heparin binding epidermal growth factor–like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma. Front. Oncol. 12:1106553. doi: 10.3389/fonc.2022.1106553

Received

23 November 2022

Accepted

29 November 2022

Published

13 December 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

12 - 2022

Updates

Copyright

*Correspondence: Kang-Yun Lee, ; Sheng-Ming Wu,

This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics